Introduction
============

Breast cancer is mortally harmful to females globally. Triple negative breast cancer (TNBC) exhibits poor prognosis, including poor distant free survival and overall survival rates ([@b1-ol-0-0-9475]). Given the lack of specific treatment for patients with TNBC, individuals are usually treated with conventional adjuvant chemotherapy ([@b2-ol-0-0-9475]), and do not experience sufficient curative effects ([@b2-ol-0-0-9475]). The lack of estrogen, progesterone and human endothelial growth factor receptor 2 receptors makes it difficult to optimize therapeutic management ([@b2-ol-0-0-9475]). Investigation into novel and specific agents is required to combat these problems.

The Janus kinase (JAK)2/signal transducer and activator of transcription (STAT)3 signaling pathway mediates the expression of various cytokines ([@b3-ol-0-0-9475]). Normally, this pathway is activated in response to certain cytokines and then regresses rapidly; however, in tumor cells, including breast cancer, lung cancer, hepatocellular carcinoma, pancreatic cancer, colorectal cancer, prostate cancer, ovarian carcinoma and gastric cancer, it is constitutively activated in a high level ([@b4-ol-0-0-9475]--[@b11-ol-0-0-9475]). Furthermore, the JAK2/STAT3 signaling pathway may modulate the expression of numerous genes and regulate various physiological functions. It targets a number of anti-apoptotic proteins, namely, B cell lymphoma-extra-large (Bcl-xL) and myeloid cell leukemia 1 (Mcl-1), in addition to cell cycle regulatory molecules and proteins associated with mitochondrial apoptosis \[Bcl2 associated X protein (Bax), Bcl2 antagonist/killer (Bak) and Caspase 3\] ([@b12-ol-0-0-9475]). Mushroom *Ganoderma lucidum*, a traditional Chinese medicine, has been demonstrated to exhibit anti-cancer effects ([@b13-ol-0-0-9475]). However, the effective components have not been well studied. Ganoderic acid A (GA-A) is one of the major bioactive Ganoderma triterpenoids isolated from *Ganoderma* and has been revealed to have an effect on lymphoma growth ([@b14-ol-0-0-9475]), as well as in the promotion of cisplatin-induced cell death by inhibiting the JAK-STAT3 signaling pathway ([@b15-ol-0-0-9475]). In addition, it suppresses cancer cell proliferation and invasion and induces apoptosis in osteosarcoma ([@b16-ol-0-0-9475]). However, the effects and mechanisms of GA-A ([Fig. 1](#f1-ol-0-0-9475){ref-type="fig"}) in human breast cancer require further investigation.

The present study aims to investigate the anticancer activity of GA-A in the human breast cancer cell line MDA-MB-231. The function of the JAK2-STAT3 signaling pathway was the focus of the present study and investigated the effects of GA-A in mitochondrial apoptosis and the cell cycle.

Materials and methods
=====================

### Materials

GA-A (96%) was purchased from Chengdu Must Bio-technology Co., Ltd., (Chengdu, China), dissolved in dimethylsulfoxide (DMSO) and maintained at 4°C. AG490, MTT, and dichloro-dihydro-fluorescein diacetate (DCFH-DA) were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). The propidium iodide (PI) staining kit and the JC-1 fluorescent dye were purchased from Beyotime Institute of Biotechnology (Nanjing, China).

### Cell culture and reagents

MDA-MB-231 breast cancer cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained with Leibovitz L-15 (L-15) medium (pH=7.3; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 100 mg/ml streptomycin, 100 IU/ml penicillin and 10% fetal bovine serum (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China). Cells were maintained at 37°C and 5% CO~2~, and the medium was refreshed every 3 days. The GA-A was diluted in L-15 immediately prior to experiments. The control group was treated with L-15 (0.01%) alone. Cells were first treated with GA-A (0.1, 0.2 and 0.4 mmol/l), then with 0.4 mmol/l GA-A and 20 µM AG490 at 37°C for 24 h. Cells were harvested at 24 or 48 h.

### Cell viability

Cell viability was investigated using an MTT assay. Cells (5×10^3^) were treated with GA-A (0.01, 0.02, 0.05, 0.1, 0.2, 0.4, 0.6 and 0.8 mmol/l) for exactly 24 h then 20 ml MTT at 5 mg/ml for 4 h at 37°C. The supernatant was then removed and 150 ml DMSO was added. After 15 min, the 490 nm optical density value was measured. The results were presented as the ratio between the control group and research group.

### Transwell invasion assay

A Transwell chamber (8 µm pore polycarbonate; Corning Incorporated, Corning, NY, USA) with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) was used in this experiment. Cells were seeded (1×10^6^) into the upper chambers of 24-transwell chamber wells and treated with GA-A (0.1, 0.2 and 0.4 mmol/l) at 37°C for 24 h. For the invasion assay, the cells were plated in the upper chamber in the serum-free L-15 medium. The medium containing 20% of FBS in the lower chamber served as a chemoattractant. Following incubation for 24 h, cells in the upper chambers were removed with a cotton swab. Subsequently, cells were fixed with 100% methanol and then stained with 1% crystal violet in 2% ethanol for 10 min at room temperature. Under a Nikon light microscope (×100), migrated cells were counted and images were captured at five different fields of the chamber.

### Cell apoptosis detection

Cells were seeded into 6-well plates (5×10^5^ cell/well) and incubated for 24 h prior to treatment. GA-A (0, 0.1, 0.2 and 0.4 mmol/l, respectively) or DMSO were added to the plate and incubated at 37°C for 1 day. Subsequently, adherent cells and non-adherent cells were digested in trypsin at 37°C for 2 min. The cell suspension was incubated with 10 ml PI and 5 ml annexin V-fluorescein isothiocyanate (from the kit aforementioned) for 10 min in the dark at 37°C and then analyzed using a flow cytometer (BD Canto II) and Diva Software v7.0 (BD Biosciences). The apoptotic index in [Fig. 3](#f3-ol-0-0-9475){ref-type="fig"} was calculated as: Apoptotic cells/total cells ×100%.

### Analysis of reactive oxygen species (ROS)

Intracellular ROS production was investigated using DCFH-DA. Cells were seeded at a density of 1×10^6^ cells/well and cultured for 24 h. Cells were then harvested in trypsin at 37°C for 2 min, washed with PBS for 5 min and re-suspended in 500 µl PBS containing 20 µM DCFH-DA then incubated at 37°C for 20 min in the dark. The cells were harvested and analyzed by flow cytometry (BD Canto II) and Diva Software v7.0.

### Western blot analysis

The treated cells (1×10^7^ cells/6 ml L-15 with 10% FBS in a 90-mm dish) were collected and washed twice using cold PBS for 5 min. Cells were lysed in 200 µl lysis radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology). The lysate was incubated on ice for 30 min, vortexed and centrifuged at 14,000 × g for 15 min at 4°C. The supernatant was collected and protein concentration was determined using a Bradford Assay. Following the addition of SDS-PAGE sample loading buffer (Beyotime Institute of Biotechnology), the protein samples (30 µg) underwent electrophoresis using a 10% SDS-PAGE and were then transferred to a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). After blocking for 4 h at room temperature in a solution of 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20, the membranes were incubated overnight at 4°C with the primary antibodies against phosphorylated (p)-JAK2 (catalog no. 3771), JAK2 (catalog no. 3230), p-STAT3 (catalog no. 9145), STAT3 (catalog no. 9139), Bcl-xL (catalog no. sc-8392), Bak (catalog no. sc-517390), Mcl-1 (catalog no. sc-12756), Bax (catalog no. sc-7480), Cytochrome c (catalog no. sc-13156) and β-actin (catalog no. sc-47778) at a concentration of 1:1,000 in Tris-buffered saline with 0.1% Tween-20 containing 5% non-fat dry milk. JAK2, p-JAK2, p-STAT3, STAT3 primary antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Bcl-xL, Bak, Mcl-1, Bax, Cytochrome c and β-actin primary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Following washing four times for 5 min, the membranes were incubated with a horseradish peroxidase-conjugated secondary anti-rabbit IgG antibody (1:5,000 dilution; catalog no. 7074; Cell Signaling Technology, Inc.) at room temperature for 1 h and were then washed six times for 10 min. Signals were detected with an enhanced chemiluminescence detection kit (Applygen Technologies, Inc., Beijing, China).

### Statistical analysis

Statistical analysis was performed using SPSS 14.0 software (SPSS Inc., Chicago, IL, USA). Values presented as the mean ± standard deviation and were analyzed using one-way analysis of variance, followed by Tukey\'s post hoc test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### GA-A inhibits MDA-MB-231 cell viability

MDA-MB-231 cells were stimulated by GA-A (0.1--0.8 mmol/l) to determine its effect on cell viability. GA-A significantly decreased cell viability compared with the control group, and the effects were not only dose dependent but also time dependent (P\<0.05; [Fig. 2A](#f2-ol-0-0-9475){ref-type="fig"}). The half-maximal inhibitory concentrations of GA-A at 24 and 48 h were 0.707 and 0.163 mmol/l, respectively.

### GA-A inhibits MDA-MB-231 cell invasive capacity

Based on the results of the Transwell invasion assay, GA-A demonstrated an inhibitory effect on the invasion of MDA-MB-231 cells. [Fig. 2B](#f2-ol-0-0-9475){ref-type="fig"} reveals that following incubation for 24 h, GA-A (0.1, 0.2 and 0.4 mmol/l) markedly decreased the number of invasive cells. As GA-A concentration increased, the MDA-MB-231 cells became less invasive. These results were consistent with the Transwell invasion assay, which indicated that GA-A suppressed the invasion of MDA-MB-231 cells.

### GA-A induces breast cancer cell apoptosis

MDA-MB-231 cells were untreated or treated with GA-A (0.1, 0.2 and 0.4 mmol/l) for 24 h. Following treatment with 0.1, 0.2 and 0.4 mmol/l of GA-A for 24 h, the apoptotic index increased by 11.34±3.41, 20.89±3.32 and 38.13±3.91%, respectively (P\<0.01, vs. control). The effect of GA-A on apoptosis was dose-dependent. These results indicate that GA-A induces apoptosis of MDA-MB-231 cells ([Fig. 3B](#f3-ol-0-0-9475){ref-type="fig"}).

### GA-A leads to ROS accumulation

As presented in [Fig. 4](#f4-ol-0-0-9475){ref-type="fig"}, ROS level markedly increased following GA-A treatment. ROS production following 0.4 mmol/l GA-A increased markedly from 27.22% in the control group to 76.35%.

### Effects of GA-A on cell cycle-regulated protein expression

Western blot analysis was applied to determine cyclin D1, p21 and p27 protein expression to further investigate the characteristics of the observed G0-G1 phase control. It was revealed that cyclin D1 expression significantly decreased compared with the control, whereas p21 and p27 expression significantly increased (P\<0.05; [Fig. 5](#f5-ol-0-0-9475){ref-type="fig"}), which indicates that distinctions exist between cell-cycle-associated protein, at least partially, leading to G0-G1 phase arrest by GA-A.

### Effects of GA-A on the JAK2/STAT3 signaling pathway and mitochondrial apoptosis

Western blot analysis was adopted to assess the phosphorylated forms of JAK2 and STAT3 in breast cancer cells stimulated by GA-A, from which the phosphorylation of these factors was revealed to significantly decrease following GA-A treatment (with the exception of p-JAK2 at 0.1 mmol/l GA-A; P\<0.05). In addition, the expression levels of Mcl-1 and Bcl-xL were significantly downregulated by GA-A dose-dependently compared with the control, in accordance with decreased phosphorylated JAK2 and STAT3 (P\<0.05; [Fig. 6](#f6-ol-0-0-9475){ref-type="fig"}). Additionally, GA-A treatment significantly enhanced the levels of mitochondrial apoptotic pathway-associated proteins (Bak, Bax, and cytosolic cytochrome C) compared with the control and in a dose dependent manner (P\<0.05), suggesting the mitochondrial apoptosis occurred.

### Effects of GA-A/AG490 combined treatment on the JAK2/STAT3 signaling pathway

The combined treatment of GA-A and AG490 further decreased JAK2/STAT3 expression levels compared with the control (P\<0.01; [Fig. 7](#f7-ol-0-0-9475){ref-type="fig"}). This result suggests that the anti-breast cancer effects of GA-A may involve other mechanisms, including JAK2/STAT3. Thus, the result supports the hypothesis that the antitumor effects of GA-A are associated with certain molecules, including Bcl-xL, Bak, Mcl-1 and Bax, and the JAK2/STAT3 signaling pathways.

Discussion
==========

In the present study, it was demonstrated that GA-A decreases cell viability, induces apoptosis and suppresses the invasion of human MDA-MB-231 cells *in vitro*. Previously, the effects of GA-A have been demonstrated in lymphoma, hepatocellular carcinoma and osteosarcoma cells ([@b12-ol-0-0-9475]--[@b14-ol-0-0-9475]), in which cellular proliferation, colony formation and invasive behaviors were revealed to be suppressed by GA-A in osteosarcoma, which is similar to the results of the present study in breast cancer.

JAK/STAT transduces a series of signals that are critical for physiological development or homeostasis. JAK1, JAK2, JAK3 and thymidine kinase 2 constitute the JAK family, which is involved in proliferation, migration and apoptosis ([@b17-ol-0-0-9475]). Constitutively activated JAKs phosphorylate a number of substrates, including STAT3; and these substrates are commonly associated with oncogenic signaling pathways ([@b18-ol-0-0-9475],[@b19-ol-0-0-9475]). STAT3 activation in regulating tumor cell metastasis, proliferation, apoptosis, invasion, migration and angiogenesis has been demonstrated in previous studies, revealing its critical function ([@b20-ol-0-0-9475]--[@b22-ol-0-0-9475]). Distinct human cancer cell lines and tumor tissues were previously studies to detect the persistent activation of STAT3 through the use of various experiments ([@b23-ol-0-0-9475]--[@b29-ol-0-0-9475]). Based on a number of previous studies, the proliferation and survival of various types of cancer were suppressed by the inhibition of STAT3 with a dominant negative form of STAT3 or other inhibitors ([@b21-ol-0-0-9475],[@b30-ol-0-0-9475]). The results of the present study revealed that the anti-MDA-MB-231 function of GA-A worked through the JAK2/STAT3 signaling pathway, and indicated that the activities of JAK2 and STAT3 were directly prohibited by GA-A treatment, which also inhibited the expression of Bcl-xL and Mcl-1. Additionally, cell viability was also further decreased by GA-A when combined with AG490. In addition to JAK2/STAT3, it was demonstrated that other mechanisms were involved in the anti-MDA-MB-231 effect of GA-A. These results suggest that a considerable number of molecules and pathways are associated with the anticancer properties of GA-A.

There are two apoptotic signaling pathways in mitochondria: One is the intrinsic, and the other is the extrinsic. The former is more commonly observed in chemotherapy ([@b31-ol-0-0-9475]), including the important members cytochrome c, caspase3, Bak and Bax ([@b32-ol-0-0-9475]). Suppression of the JAK2/STAT3 signaling pathway induces apoptosis through the mitochondrial apoptotic pathway ([@b33-ol-0-0-9475],[@b34-ol-0-0-9475]). Additionally, one of the sources for ROS is from the mitochondria during the process of apoptosis ([@b35-ol-0-0-9475]). The results of the present study demonstrate that GA-A significantly increased expression of proteins associated with ROS generation and mitochondrial apoptosis. This supported previous studies that suggested that for human cancer cells, mitochondrial apoptosis is associated with inhibiting JAK2/STAT3 ([@b33-ol-0-0-9475],[@b34-ol-0-0-9475]).

As a cell cycle regulator, cyclin D1 regulates G1 cells entering the S-phase and serves a function as a cofactor for a number of transcription factors ([@b36-ol-0-0-9475]). Cyclin D1 overexpression may contribute to cancer incidence ([@b37-ol-0-0-9475]). p21 and p27, as CDK inhibitors (CDKIs), attenuate cancer cell proliferation with their upregulation ([@b38-ol-0-0-9475]). It has previous been demonstrated that JAK2/STAT3 phosphorylation is suppressed by WP1193 inhibiting glioma stem-like cell proliferation and sphere formation; the reason for this effect partially lies in decreased cyclin D1 and increased p21 expression ([@b39-ol-0-0-9475]). Research on colon cancer cells also suggests that STAT3 controls the balance between CDK/cyclin and CDKIs ([@b34-ol-0-0-9475]). The present study demonstrated that GA-A treatment may result in delays in the cell cycle in G0-G1 phase. Furthermore, a decrease was observed in cyclin D1 expression but conversely an increase in p21 and p27 expression in MDA-MB-231 cells following GA-A treatment, compared with the control. Collectively, the results of the present study provide supporting evidence for JAK2/STAT3 in the counterpoise.

According to the result of the present study, GA-A treatment inhibits MDA-MB-231 cell viability by inhibiting the JAK2/STAT3 signaling pathway, and GA-A regulates various targets that jointly generate the anti-MDA-MB-231 effects. These effects include affecting the pathways involved in the mitochondrial apoptosis and cell cycle control.
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GA-A

:   Ganoderic acid A

![Structure of Ganoderic acid A.](ol-16-05-6515-g00){#f1-ol-0-0-9475}

![GA-A inhibited the viability and invasive capacity of MDA-MB-231 cells. (A) GA-A inhibited MDA-MB-231 cell viability in a dose and time dependent manner. \*P\<0.05 vs. control group, \*\*\*P\<0.001 vs. control. (B) GA-A inhibits MDA-MB-231 cell invasive capacity. GA-A, Ganoderic acid A.](ol-16-05-6515-g01){#f2-ol-0-0-9475}

![GA-A induced the apoptosis of MDA-MB231 cells. (A) GA-A induced MDA-MB-231 apoptosis as measured by flow cytometry and (B) quantified. \*\*P\<0.01 vs. control, \#\#P\<0.01 vs. GA-A 0.1 mmol/l group, ŞŞP\<0.01 vs. GA-A 0.2 mmol/l group. GA-A, Ganoderic acid A; PE, phycoerythrin; FITC, fluorescein isothiocyanate.](ol-16-05-6515-g02){#f3-ol-0-0-9475}

![GA-A upregulated reactive oxygen species levels in MDA-MB-231 cells. MDA-MB-231 cells were (A) untreated or treated with GA-A (B) 0.1 mmol/l, (C) 0.2 mmol/l and (D) 00.4 mmol/l for 24 h. GA-A, Ganoderic acid A.](ol-16-05-6515-g03){#f4-ol-0-0-9475}

![GA-A affected the expression of cell cycle association proteins cyclin D1, p21 and p27 in MDA-MB-231 cells. (A) Western blot analysis and (B) quantified relative expression. \*\*\*P\<0.001, \*\*P\<0.01, \*P\<0.05 vs. GA-A-untreated control. GA-A, Ganoderic acid A; n.s., not significant.](ol-16-05-6515-g04){#f5-ol-0-0-9475}

![GA-A affected JAK2/STAT3 signaling pathway and mitochondrial apoptotic pathway associated proteins in MDA-MB-231 cells. (A) The bands of western blot analysis. β-actin was used as an internal control. (B) Statistical charts of the relative expression levels of t-JAK2 and p-JAK2. (C) Statistical charts of the relative expression levels of t-STAT3 and p-STAT3. (D) Statistical charts of the relative expression levels of Bcl-xL. (E) Statistical charts of the relative expression levels of Mcl-1. (F) Statistical charts of the relative expression levels of Bax. (G) Statistical charts of the relative expression levels of Bak. (H) Statistical charts of the relative expression levels of cytosolic Cytochrome c. \*\*\*P\<0.001, \*\*P\<0.01, \*P\<0.05 vs. GA-A-untreated control. GA-A, Ganoderic acid A; STAT, signal transducer and activator of transcription; JAK, Janus kinase; Bcl-xL, B cell lymphoma-extra-large; Mcl-1, myeloid cell leukemia 1; Bax, Bcl2 associated X protein; Bak, Bcl2 antagonist/killer; n.s., not significant; p-, phosphorylated; t-, total.](ol-16-05-6515-g05){#f6-ol-0-0-9475}

![Effects of GA-A combined with AG490 on JAK2/STAT3 signaling. (A) The bands of western blot analysis. β-actin was used as an internal control. Relative expression levels of (B) p-JAK2 and (C) p-STAT3. \*\*\*P\<0.001, \*\*P\<0.01, \*P\<0.05 vs. GA-A-untreated control. GA-A, Ganoderic acid A; STAT, signal transducer and activator of transcription; JAK, Janus kinase; n.s., not significant; p-, phosphorylated; t-, total.](ol-16-05-6515-g06){#f7-ol-0-0-9475}
